Document is current
Any future updates will be listed below
-
Authors
Nasr, Patrik http://orcid.org/0000-0002-2928-4188
von Seth, Erik http://orcid.org/0000-0002-6976-248X
Mayerhofer, Raphaela http://orcid.org/0000-0003-1441-6819
Ndegwa, Nelson http://orcid.org/0000-0001-5297-5107
Ludvigsson, Jonas F. http://orcid.org/0000-0003-1024-5602
Hagström, Hannes http://orcid.org/0000-0002-8474-1759
-
Funding
Funding for this research was provided by:
ALF Grants, Region Östergötland
Lion Research Grant, Faculty of Medicine, Linköping University
Region Stockholm
Cancerfonden
Vetenskapsrådet
Karolinska Institute
- License Information
-
More Information
Article History
Received: 19 January 2023
Accepted: 26 June 2023
First Online: 25 July 2023
Declarations
:
: Dr Ludvigsson has coordinated a study on behalf of the Swedish IBD quality register (SWIBREG). That study received funding from Janssen corporation. Dr Ludvigsson has also received financial support from MSD. Erik von Seth has received funding from Gilead Sciences Europe Ltd for epidemiological research on primary sclerosing cholangitis. Dr Hagström has received consulting fees from Astra Zeneca and Dr Hagström’s institutions have received research grants from Astra Zeneca, EchoSens, Gilead, Intercept, MSD and Pfizer.
: This study was based on aggregated, anonymous data and therefore ethical approval or informed consent was not required(CitationRef removed).
: Waived because of registry-based nature.
: Waived because of registry-based nature.
: No patients were involved in setting the research questions or the outcome measures, nor were they involved in developing plans for the design of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community.
